Neal Walker - Jan 3, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jan 3, 2023
Transactions value $
-$604,556
Form type
4
Date filed
1/4/2023, 05:20 PM
Previous filing
Jun 9, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$355K -23.4K -1.88% $15.19 1.22M Jan 3, 2023 Direct F1, F2
transaction ACRS Common Stock Sale -$26.1K -1.62K -0.13% $16.16 1.22M Jan 3, 2023 Direct F1, F3
transaction ACRS Common Stock Sale -$223K -15K -1.23% $14.89 1.21M Jan 4, 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2022.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.89 to $15.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.92 to $16.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.